Kornimate/medical-research-clean huggingface dataset:
effects of the anti-hiv pill truvada on gene transcription in the gastrointestinal tract of hiv-uninfected individuals

Conditions: HIV

Summary: as explained in detail in a recently published hypothesis article (hladik f. a new hypothesis on hiv cure. f1000research, 4:77 (2015)), the investigators hypothesize that nrti drugs may reduce the likelihood of hiv eradication by promoting the survival of cells with integrated provirus. in this study, the investigators will test whether daily oral use of two ntri drugs, tenofovir and emtricitabine (truvada pill), induces changes in the upper and lower gut mucosa that are congruent with supporting this hypothesis.


Eligibility criteria:
inclusion criteria: * • hiv-negative * male gender at birth * age ≥18 years old * intent to initiate prep in the next 1-2 months. * willingness and ability to provide informed consent for study participation * willingness to undergo all required study procedures exclusion criteria: * creatinine clearance \< 60ml/min * platelet count below the normal reference * coagulation (pt/ptt) tests above the normal reference * any prior use of prep * use of pep within 30 days prior to study entry * receipt of * anti-coagulant medications (e.g. warfarin). aspirin is allowable. * systemic corticosteroid medications * non-steroidal anti-inflammatory drug (nsaid) use \>2 days/week * signs or symptoms of acute hiv infection within 14 days of study entry * no availability of another person who will drive participant home on days of entry and follow-up procedures. * plan to leave the seattle area in the subsequent 2.5 months * any condition or substance use that, in the opinion of the study investigator, would interfere with study participation.
to evaluate pharmacokinetics (pk) and safety of tavapadon in participants with severe renal impairment compared to participants with normal renal function

Conditions: Renal Impairment

Summary: the primary purpose is to assess the effect of renal impairment on the pk of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.


Eligibility criteria:
key inclusion criteria: 1. body mass index of ≥18.0 to 40.0 kilograms per meter square (kg/m\^2), inclusive, and a total body weight \>50 kilograms (kg) \[(110 pounds (lbs)\]. 2. age that is within ±10 years of the median age for the severe renal impairment cohort. bodyweight that is within ±15 kg of the median bodyweight for the severe renal impairment cohort. 3. severe renal function: estimated glomerular filtration rate (egfr) \<30 ml/min (not requiring dialysis) determined using chronic kidney disease epidemiology collaboration (ckd-epi) equation. 4. stable disease, defined as no clinically significant changes in disease status as documented by the most recent egfr assessment (within at least 3 months before screening). 5. stable concomitant medications for the management of individual participants medical history. key exclusion criteria: 1. serious risk of suicide in the opinion of the investigator. 2. history of substance or alcohol use disorder (excluding nicotine or caffeine) within 12 months prior to signing the informed consent form (icf). 3. receipt of severe acute respiratory syndrome coronavirus 2(sars-cov2) vaccine or booster within 7 days of planned dosing. 4. have recently been diagnosed with symptomatic coronavirus disease 2019 (covid-19) or test positive for covid-19 within 30 days prior to signing the icf. 5. positive drug screen including tetrahydrocannabinol (thc). 6. positive result for human immunodeficiency virus (hiv) antibody, hepatitis b surface antigen, hepatitis b core antibody, or hepatitis c antibody with detectable viral ribonucleic acid (rna) levels at screening. 7. positive drug screen including thc (except with a vail prescription other than medical marijuana). 8. participants who have received an organ transplant or are currently waiting for an organ transplant and are listed on the national transplant list. 9. participants who require dialysis. 10. participant with nephrotic syndrome. 11. abnormal hemoglobin. 12. abnormal blood pressure measurement or heart rate at screening or check-in. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: healthy volunteer severe renal impairment
renal resistive index as a predictor of renal involvement in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: evaluation of resistive index on the renal artery as early predictor factor of renal affection in patients with rheumatoid arthritis.

rheumatoid arthritis (ra) is a chronic autoimmune disorder characterized by synovial hyperplasia and inflammation, progressive joint destruction, and significant disability (1). it can occur at any age, but it predominantly affects women, with a peak onset between the ages of 40 and 60. ra etiology is not yet clear, recent studies have shown that its mechanism is closely related to genetics, environment, and immune response. genes such as mhc and hla-dr4 are involved in the occurrence of ra. (2) renal complications in ra can range from mild abnormalities in kidney function to more severe conditions, such as glomerulonephritis and renal amyloidosis. understanding these renal complications is crucial for healthcare providers to ensure comprehensive care for ra patients. (3.4) vasculitis is an uncommon complication of ra (in approximately 2 to 5% of patients), males with ra are more likely (2 to 4 times more likely) than females with ra to develop rv. rheumatoid vasculitis most often occur in people with at least 10 years of severe disease. fortunately, recent reports have noted declines in the prevalence of rv ( 5.6). so the renal arterial resistive index (ri)which is a sonographic index of intrarenal arteries defined as (peak systolic velocity - end-diastolic velocity) / peak systolic velocity. the normal range is 0.50-0.70. elevated values are associated with poorer prognosis in various renal disorders .

Eligibility criteria:
inclusion criteria: * patients of rheumatoid arthritis è renal affection * patients of rheumatoid arthritis without renal affection * patients of rheumatoid arthritis on drugs (nsaids, dmards, methotrexate..). exclusion criteria: * diabetic and hypertensive patients, patients with hepatitis b, c viruses or liver cell failure, patients with acute kidney injury, patients with another autoimmune disease as (sle, sjogren disease, multiple sclerosis, patients with malignancy, patients on another drugs otherwise rheumatoid arthritis drugs).
a study of onartuzumab (metmab) in combination with bevacizumab (avastin) plus platinum and paclitaxel or with pemetrexed plus platinum in patients with non-squamous non-small cell lung cancer

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of ro5490258 (metmab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable stage iiib or iv non-squamous non-small cell lung cancer. in cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either metmab 15 mg/kg iv or placebo on day 1 of each 21-day cycle. in cohort 2, patients will be randomized to receive pemetrexed 500 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either metmab 15 mg/m2 iv or placebo on day 1 of each 21-day cycle. patients who have not progressed after 4 cycles will be offered maintenance therapy with their assigned treatment of bevacizumab plus either metmab or placebo (cohort 1) or pemetrexed plus either metmab or placebo (cohort 2). anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * histologically or cytologically confirmed stage iiib or stage iv non-squamous non-small cell lung cancer (nsclc) * eastern cooperative oncology group (ecog) performance status 0 or 1 * for patients who received prior adjuvant chemotherapy or chemoradiotherapy: a treatment-free interval of at least 12 months since last chemotherapy or chemoradiotherapy cycle * adequate tissue for central immunohistochemical (ihc) assay of met receptor, and epidermal growth factor receptor (egfr) testing if egfr status is unknown * radiographic evidence of disease exclusion criteria: * prior systemic treatment for stage iiib or iv non-squamous nsclc * evidence of mixed nsclc with a predominance of the squamous cell type * prior exposure to experimental treatment targeting either the hepatocyte growth factor (hgf) or met pathway * patients with tumors confirmed to have egfr-activating mutations who are suitable for anti-egfr therapy (e.g. gefitinib or erlotinib), as determined by the investigator, unless that treatment is unavailable or refused by the patient * known central nervous system (cns) disease, other than stable, treated brain metastases * history of another malignancy in the previous 3 years, except for history of in situ cancer that was treated surgically with curative intent, localized prostate cancer that has been treated surgically with curative intent, or basal or squamous cell skin cancer * uncontrolled diabetes * pregnant or lactating women * impaired bone marrow, liver or renal function (as defined by protocol) * significant history of cardiovascular disease * positive for hiv infection
nonintubated thoracic epidural anesthesia versus double-lumen intubated anesthesia in video-assisted thoracic surgery

Conditions: Anaesthesia; Video Assisted Thoracic Surgery

Summary: the purpose of this study is to compare results of general video-assisted thoracic surgery (vats) operations under no-intubated thoracic epidural anesthesia (ntea) versus those of a control group operated under general anesthesia with double-lumen endotracheal intubation.

the thoracoscopic surgery always requires not only an appropriate depth of anaesthesia, but also a quiet and wide operative field. that's why anaesthesia plays a critical role in thoracoscopic surgery. general double-lumen endotracheal intubated anesthesia with one-lung ventilation, has been accepted mandatory for video-assisted thoracic surgery (vats) although several adverse effects can derive from this type of anesthesia like intubation-related throat injury, ventilator-induced lung injury, arrhythmia and so on. the investigators hypothesize that vats could be performed under the no-intubated thoracic epidural anesthesia (ntea) to avoid general anesthesia related risks. some cases have been reported to prove the safety and feasibility of ntea in uncomplicated vats. however, the comparison of ntea and general anesthesia has been rarely investigated in such a larger magnitude number and such operation varieties. the investigators hypothesize ntea could result in less inflammations, lower incidence of complications, less dosage of antibiotic, faster recovery eventually leading to a shorter hospital stay. for this reason, the investigators will undertaken a randomized trial comparing results of general vats operations under ntea versus those of a control group operated under general anesthesia with double-lumen endotracheal intubation. a total of 500 patients will be included. the study will be performed in the first affiliated hospital of guangzhou medical college.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years old * signed inform consent * tumor size \< 6 cm without right or left bronchus invasion * predicted fev 1.0 \> 60% or fev1.0 \> 1.5l * ef \> 50% * pco2 \ 60mmhg（without uptaking oxygen） exclusion criteria: * psychopath patients who cannot cooperate * asa score greater than 3 * a history of tuberculosis or other signs of intrapleural adhesions * spinal malformation * hypovolemia or coagulation disorders * bmi \> 30 * unfavorable reasons judged by anesthesiologist or surgeon

Keywords: nonintubated anaesthesia vats
effect of slopped shoulder implant neck vs conventional implant neck design on crestal bone level in the maxilla

Conditions: Missing Tooth

Summary: in implant dentistry, platform switching is a method used to preserve alveolar bone levels around dental implants. the concept refers to using an implant with slopped shoulder neck of narrower diameter on implants of wider diameter, rather than placing abutments of similar diameter, referred to as platform matching.the aim of the study is to compare the effect of bone-level implants versus the conventional implant on oral soft tissues.

implant prosthesis allows normal muscle function, and the implant stimulates the bone and maintains its dimensions in a manner similar to healthy natural teeth. crestal bone loss can result in increased bacterial accumulation resulting in secondary peri-implant inflammation and bone loss which can further result in loss of alveolar support, which in turn can lead to occlusal overload resulting in implant failure. in implant dentistry, platform switching is a method used to preserve alveolar bone levels around dental implants. the concept refers to using an implant with slopped shoulder neck of narrower diameter on implants of wider diameter, rather than placing abutments of similar diameter, referred to as platform matching. the authors developed the concept of slopped shoulder implant which results in an inward bone creeping at the coronal part of the implant to be in continuity with the alveolar bone crest. the rational to use this type of implant allows an increase at residual crestal bone volume around the implant neck and has 3 merits: 1. reduced mechanical stress at the implant neck area; 2. repositioning of gingival papillae on the beveled neck implant (that is the physiologic condition); 3. proper vascular supply to the implant investing structure and bone tissue also because of reduced inter-implant space. the aim of the study is to compare the effect of bone-level implants versus the conventional implant on oral soft tissues

Eligibility criteria:
inclusion criteria: * good oral hygiene * systemically healthy (free from any systemic diseases). * adequate native bone to achieve implant primary stability * have had the tooth extraction at least 3 months before implant surgery. * did not receive soft or hard tissue augmentation before or in conjunction with implant surgery exclusion criteria: * smokers * pregnant woman * had a history of alcoholism or drug abuse within the past 5 years. * had bruxism or clenching habits. * patients who refused to join the study. * had significant untreated periodontal disease or history of treated periodontitis. * had caries on teeth adjacent to the prospective implant site. * periapical infection. * localized radiation therapy of the oral cavity; antitumor chemotherapy. * poor oral hygiene
diagnosing of acute tuberculosis

Conditions: Tuberculosis

Summary: sweat proteins are analysed to investigate differences in protein markers in patients with acute tuberculosis and other pulmonary diseases (pneumonia, bronchitis, chronic obstructive pulmonary disease (copd)) and healthy individuals. differences in sweat protein markers in patients with positive and negative tuberculosis enzyme-linked-immuno-spot (elispot) are investigated. differences in sweat protein markers in the course of treatment in patients receiving tuberculostatic therapy are investigated.


Eligibility criteria:
inclusion criteria: * adult patients * ability to understand the purpose of the study, provide signed and dated informed consent by patient or his/her legal representative * in-patients with acute tuberculosis, suspected tuberculosis or other pulmonary diseases (pneumonia, bronchitis, copd) inclusion criteria healthy donors: * negative for quantiferon- tb gold plus test or elispot exclusion criteria: * initiation of tuberculostatic therapy before baseline * initiation of antibiotic therapy in patients with other pulmonary diseases \> 6 hours before baseline

Keywords: sweat protein markers in tuberculosis
evaluation of the sensitivity of merz lips fullness assessment scale following etermis 4® treatment for lips volume augmentation

Conditions: Subjects Desiring Lip Augmentation

Summary: primary objective: - to evaluate the sensitivity of the merz lip fullness assessment scale (mlfas). secondary objectives: * to evaluate the clinical aesthetic improvement outcome in lips appearance four weeks after etermis 4® injection. * to evaluate safety/tolerability of etermis 4® treatment in lips.


Eligibility criteria:
inclusion criteria: * healthy male or female study subjects with thin to medium lips volume (grade 1 to 2 on mlfas), seeking for hyaluronic acid (ha) for lips volume augmentation in ≥1-point improvement on the mlfas on both the upper and lower lips and fulfilling the criteria listed in the instruction for use (ifu) of the study medical device to be injected. exclusion criteria: * subjects with a medical condition and/or medication according to current ifu which is contra indicated for ha filler treatment, or prior facial surgeries or surgical permanent implants, lips augmentation treatment or other aesthetic procedure in the face that could interfere with performance assessment.
prevalence of primary aldosteronism in patients with resistant hypertension in china

Conditions: Hypertension, Resistant to Conventional Therapy

Summary: recent studies indicate that primary aldosteronism (pa) is a much more common cause of hypertension than had been demonstrated historically. in patients with resistant hypertension, the prevalence of pa from different clinics worldwide is about 10-20%. as has been no such data in china, the investigators are conducting a pa study in different province of china to evaluate the prevalence of pa in patients with resistant hypertension.


Eligibility criteria:
inclusion criteria: * patients with resistant hypertension * age 18-65 years exclusion criteria: * known cause of hypertension * heart failure * renal dysfunction * stroke, transient ischaemic attack or myocardial infarction in the past 6 months * cirrhosis * pregnancy * undertreatment of glucocorticoid
the effect of processed tomato products on cvd risks

Conditions: Cardiovascular Disease

Summary: the primary working hypothesis is that consuming processed tomatoes frequently/daily will favorably improve endothelium and platelet function disease-risk biomarker profiles in adult men and women compared to consuming no or relatively low amounts of processed tomatoes.


Eligibility criteria:
inclusion criteria: men and women (\>21 \<70 years) nonsmokers, with a body mass index (bmi) ranging of 25 to 35 kg/m2, bp \< or = 140/90 mmhg exclusion criteria: 1. total cholesterol (tc) is greater than 300 mg/dl; 2. fasting triglyceride is greater than 300 mg/dl; 3. ldl cholesterol (ldl-c) is greater than 180 mg/dl; 4. female subjects who are pregnant or lactating; 5. subjects who are actively losing weight or trying to lose weight; 6. subjects with known allergy or intolerance to tomato products; 7. taking any medications that would interfere with outcomes of the study, ie. lipid lowering medications, anti-inflammatory drugs, dietary supplements, such as fish oil or evening primrose; 8. subjects' with documented atherosclerotic disease, inflammatory disease, diabetes mellitus, uncontrolled hypertension (\>=140/90 mm hg - ok if controlled below this limit with medication), or other systemic diseases; 9. subjects with low hematological counts as determined by \>or \<15% the upper or lower cut-off values of normal established for the lab; 10. smokers. -

Keywords: cardiovascular disease lycopene tomato
probiotic (vsl #3) for gulf war illness

Conditions: Gulf War Illness

Summary: the overall objective is to determine whether vsl #3 will improve 1) intestinal symptoms of irritable bowel syndrome (ibs) and 2) non-intestinal symptoms (fatigue, joint pain, insomnia, general stiffness and headache) associated with ibs. all of these symptoms are part of the gulf war (gw) illness.

specific aims: aim # 1: determine the efficacy of vsl #3 on ibs symptoms in gw veterans. hypothesis: treatment with vsl #3 compared to placebo will improve global and individual symptoms of ibs aim #2 determine the efficacy vsl #3 in reducing non-intestinal symptoms of ibs (fatigue, joint pain, insomnia, general stiffness and headache). hypothesis: treatment with vsl #3 compared to placebo will improve non-intestinal symptoms of ibs in gw veterans. aim #3 determine whether changes in gut flora and plasma cytokines correlate with treatment response in gw veterans.

Eligibility criteria:
inclusion criteria: 1. first gw veterans, men and women age 35-75 years, 2. rome iii criteria for ibs and two or more of the non-intestinal symptoms (chronic-once a week or more often-fatigue, joint pains, insomnia, general stiffness, and headache) 3. symptoms of \> 6 months duration, 4. no significant findings on physical examination, complete blood count (cbc) and clinical chemistry panel. 5. normal gross appearance of the colonic mucosa other than erythema and polyps 6. negative tissue transglutaminase (ttg) for celiac disease, 7. normal thyroid function. 8. veterans with psychological disorders will not be excluded but will be identified for sub-group analysis. 9. stable medication regimen for more than a month exclusion criteria: 1. current evidence of any lower gastrointestinal disorder such as celiac disease or inflammatory bowel disease 2. history of/or presence of systemic malignancy (patients with skin and other cancers in remission for more than 5 years are allowed in the study 3. clinically significant chronic disease: hiv, cardiac, pulmonary, hepatic or renal dysfunction. 4. presence of giardia antigen, and clostridium difficile toxin in stool, 5. abnormal blood test for thyroid stimulating hormone, tissue transglutaminase antibody 6. current effects of drug or alcohol abuse 7. investigator perception of patient's inability to comply with study protocol 8. recent change in gastrointestinal medications 9. use of any antibiotic in the last 1 months 10. positive pregnancy test 11. subject is currently participating in another research protocol that could interfere or influence the outcome measures of the present study.

Keywords: irritable bowel syndrome gulf war illness
telomere parameters in patients with nonalcoholic fatty liver

Conditions: FATTY LIVER; NO MALIGNANCY; NO DECOMPENSATED ILLNESS

Summary: telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. non-alcoholic fatty liver disease (nafld) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. the risk factors for that evolution are not fully understood. our group showed in a previous study, that htert mrna expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. this finding could explain the telomere shortening found previously in these patients by our group \[20\] and others \[21\]. furthermore, we found higher rates of tc in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. this is through a different mechanism that is not telomerase-mediated. telomere capture is considered an alternative way to maintain telomere length and chromosomal stability \[3\]. it is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation this study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with nafld in order to explain previous findings of telomere shortening in these patients.


Eligibility criteria:
inclusion criteria: * age over 18 * diagnosis of fatty liver exclusion criteria: * no malignancy * no eligible to sign the consent paper